Description

Oxiracetam Powder

Oxiracetam
CAS Number	62613-82-5
Molar Mass	158.155 g·mol−1
Chemical Formula	C6H10N2O3
IUPAC Name	(RS)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide

Introduction

Oxiracetam Powder is a meticulously formulated research product developed exclusively for scientific exploration, with a strict emphasis on its application in research and the exclusion of any mention of human consumption. This compound serves as a valuable tool for researchers investigating its unique properties and potential benefits in various research domains.

Key Characteristics

Oxiracetam is a member of the racetam class of nootropic compounds, known for its potential cognitive-enhancing effects. Its distinct characteristics make it a subject of interest in research focused on cognitive function and neuroprotection.

Research Applications

Oxiracetam Powder finds versatile applications in research domains, offering researchers a tool to explore its potential benefits. Its applications extend to investigations into dementia, memory enhancement, and potential neuroprotective effects.

Research Benefits

Oxiracetam and Dementia

Studies suggest that Oxiracetam may have potential applications in addressing cognitive decline associated with dementia. Research in this domain aims to understand its mechanisms of action and potential therapeutic applications in dementia-related conditions.

Oxiracetam and Memory

Preliminary research indicates that Oxiracetam may have cognitive-enhancing effects, particularly in the context of memory improvement. Investigations into its impact on memory processes contribute to understanding its potential applications in memory-related conditions.

Oxiracetam and Neuroprotection

Research suggests that Oxiracetam may have implications for neuroprotection, potentially influencing neuronal survival and function. Studies exploring its effects on neuroprotection contribute to understanding its potential applications in preserving overall brain health.

Summary

Oxiracetam Powder, developed exclusively for research purposes, provides researchers with a unique avenue for investigating its potential benefits in dementia, memory enhancement, and neuroprotection. The distinctive characteristics of Oxiracetam make it a promising subject for further exploration in neuroscientific and cognitive research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Bottini G, Vallar G, Cappa S, Monza GC, Scarpini E, Baron P, Cheldi A, Scarlato G. Oxiracetam in dementia: a double-blind, placebo-controlled study. Acta Neurol Scand. 1992 Sep;86(3):237-41. doi: 10.1111/j.1600-0404.1992.tb05077.x. PMID: 1414239. [Read More].
2. Saletu B, Linzmayer L, Grünberger J, Pietschmann H. Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life. Neuropsychobiology. 1985;13(1-2):44-52. doi: 10.1159/000118161. PMID: 3897895. [Read More].
3. Rozzini R, Zanetti O, Bianchetti A. Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. Acta Neurol (Napoli). 1993 Feb;15(1):44-52. PMID: 8456595. [Read More].